Vanda Pharmaceuticals Inc (NASDAQ:VNDA) Shares Dropped By 3.09%

718

Dallas, Texas 11/21/2013 (Financialstrend) – In Wednesday’s trading session, Vanda Pharmaceuticals Inc (NASDAQ:VNDA) dropped by 3.09%. The opening price of the shares was $12.03, which climbed to an intraday high of $12.19 and headed to close at $11.62. Around 0.886M shares were exchanged on Wednesday while the average-volume of 2.47 million shares were traded over a 30 day period. The 52-week low of Vanda Pharmaceuticals Inc (NASDAQ:VNDA) shares is $3.00 while the 52-week high is $15.65. The company has a market capitalization of $385.67 million.

About the company

Vanda Pharmaceuticals Inc (NASDAQ:VNDA was formed on 13th November 2002 and is a bio-pharmaceutical company. It focuses on developing and commercializing products that are used to treat disorders in the central nervous system. Vanda Pharmaceuticals Inc (NASDAQ:VNDA) product-portfolio includes tasimelteon- this is a compound that is used to treat circadian rhythm-sleep disorders (CRSD). It is in clinical-development for Non-24. The company’s other product- Fanapt is a compound that is used to treat schizophrenia. It is an oral formulation that is being marketed & sold in the U.S by Novartis Pharma AG. The other drug is VLY-686- this is a small molecule neurokinin-1-receptor (NK-1R)-antagonist.

Tasimelteon

Tasimelteon is a circadian-regulator that is in development treating Non-24. Tasimelteon is the melatonin agonist of the human-MT1 & MT2 receptors that has a greater specificity of MT2. Tasimelteon’s ability to be able to reset the master body-clock in the suprachiasmatic-nucleus (SCN), that is located in the hypothalamus, leads to the entrainment of the body melatonin & cortisol rhythms and aligns to the 24-hour day & night cycle. Tasimelteon has also shown to significantly-improve clinical symptoms in numerous sleep &wake measures.

Fanapt
Fanapt is the compound that is used to treat schizophrenia. Novartis has the exclusive commercialization rights to formulations of Fanapt in the U.S and Canada. Novartis is also responsible for the further clinical-development activities in the U.S and Canada

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.